Greetings, and welcome to the Pulse Biosciences' Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session ...

European Society of Cardiology (ESC) guidance advises that treatment should last for at least six weeks in patients with ...

And then Mike Koffler, Vice President of Finance will review the third quarter, 2024 financial results. Then we will be joined by Bob Duggan, cochair of the board, Darren Eker, Chief Technology ...

Holdings announced the completion of the first procedures in FULCRUM-VT U.S. Food and Drug Administration FDA Pivotal ...

Currently, echocardiographic contrast agents are indicated for LV opacification and endocardial border definition in patients with technically suboptimal studies. The two FDA approved agents in ...

rch.org.au The precise mechanisms leading to congenital aortic valve lesions have not yet been fully elucidated. The predominant theory is that the aortic valve arises from the moulding of three ...

Experience with 110 separate periods of transvenous cardiac pacing by means of a catheter-electrode in 91 patients has been reviewed. Indications for the use of the catheter-electrode included (1) ...

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary ...

Congestive heart failure is a disease state distinguished by the regular presence of both renal and hepatic abnormalities in drug handling. One such abnormality involves flaws in the process of ...